Recession USA 2020

NantKwest in Pact with Generate Life’s CBR on potential COVID-19 treatment (NASDAQ:NK)

Cord Blood Registry (CBR) by Generate Life Sciences and NantKwest (NK +6.7%) announces collaboration for development of COVID-19 treatment leveraging newborn stem cells.

CBR will provide research-donated umbilical cord tissue-derived mesenchymal stem cells

Patient trials expected to begin in the fall, and both companies anticipate an FDA-approved treatment to be in the market for use in Covid-19 patients by early 2021.

Related posts

Dow Jones Futures: Great Stock Market Rallies Are Bad Teacher; Analyzing Tesla, Bitcoin, Microsoft

Investors are punishing Walmart for raising workers’ pay

Qumu reaffirms FY20 revenue outlook (NASDAQ:QUMU)

Leave a Comment